Monopar Therapeutics valuation and forecast
Explore the models for Monopar Therapeutics, adjust their assumptions and compare your own valuation with the platform's.
Stock price today
Loading chart…
Third-party market data · may be delayed
Fair value per share
Under review: every model's value for Monopar Therapeutics is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.
Price vs value
Under review: limited reported history: available models are shown without a Buy/Hold/Sell rating. We'll show the comparison once resolved.
Analyst recommendations
Monthly trend
- Oct 202612
- Sep 202613
- Aug 202613
Counts of recommendations published by analysts covering Monopar Therapeutics, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.
Price history
Loading chart…
Third-party market data · may be delayed
MNPR valuation questions
- How does Fundamentalytics value Monopar Therapeutics?
- We use the models that fit Monopar Therapeutics's business and available financial data. Each model has its own assumptions and data requirements. The calculator explains which models are available and lets you adjust their inputs.
Data: SEC EDGAR filings, retrieved Invalid Date. Method: how we value companies. Disclosures: research and recommendations disclosure. Back to Monopar Therapeutics.